title: Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS).
abstract: BACKGROUND
  The assessment of the impact of neoadjuvant therapy on quality of life (QL) has rarely been prospectively planned and evaluated, although validated QL instruments are available-such as the Lung Cancer Symptom Scale (LCSS) used in this study. The modest but significant survival gains reported with neoadjuvant and adjuvant approaches need to be viewed in terms of the added risks and toxicities associated with two or three modalities of treatment.
  
  
  METHODS
  The objective was to compare patient-determined QL ratings from baseline (prior to neoadjuvant chemotherapy) with those in subsequent months of follow-up. All patients had clinical stage I or II non-small cell lung cancer (NSCLC) and participated in one of two similar randomized protocols. Patients received preoperative chemotherapy (three cycles) of gemcitabine plus carboplatin or paclitaxel in one trial or gemcitabine plus carboplatin or cisplatin in the second. Patients completed the LCSS at baseline, every 3 weeks preoperatively, and every 3 months postoperatively up to 12 months.
  
  
  RESULTS
  Full QL data are available for 43 patients with at least one postsurgical evaluation and for 23 patients with evaluation at 1-year postsurgery. In patients with at least one postsurgical evaluation, 84% had an ECOG performance status of 0, 93% had a complete resection, and 67% (95% CI = 52, 81) of patients experienced improved or stable symptoms. A subgroup of patients (14 of 43) reported worsening of QL (33%). These patients experienced a mean worsening of 66% in individual symptom parameters, with an average of seven of nine LCSS symptom parameters declining.
  
  
  CONCLUSIONS
  Most patients reported improved or stable QL. Prospectively planned QL assessment is feasible with neoadjuvant trials and adds useful information not otherwise attainable.
authors.affiliation: North Shore-LIJ Health System, 450 Lakeville Rd, Lake Success, NY 11042, USA. rgralla@nshs.edu
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Gralla
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Edelman
authors.forename: Frank C
authors.initials: FC
authors.lastname: Detterbeck
authors.forename: Thierry M
authors.initials: TM
authors.lastname: Jahan
authors.forename: David M
authors.initials: DM
authors.lastname: Loesch
authors.forename: Steven A
authors.initials: SA
authors.lastname: Limentani
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
authors.forename: Guangbin
authors.initials: G
authors.lastname: Peng
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Monberg
authors.forename: Coleman K
authors.initials: CK
authors.lastname: Obasaju
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000523:psychology* / Q000628:therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000523:psychology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
references.citation: J Thorac Oncol. 2008 Jan;3(1):30-6
references.pmid: 18166838
references.citation: Eur J Cancer. 1993;29A Suppl 1:S51-8
references.pmid: 8381294
references.citation: J Clin Oncol. 2008 Jan 10;26(2):233-41
references.pmid: 18086802
references.citation: Support Care Cancer. 1994 Jul;2(4):213-22
references.pmid: 8087439
references.citation: Ann Oncol. 1997 Jun;8(6):525-9
references.pmid: 9261520
references.citation: J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491
references.pmid: 11882819
references.citation: Lung Cancer. 1999 Oct;26(1):7-14
references.pmid: 10574676
references.citation: Chest. 2000 Feb;117(2):374-9
references.pmid: 10669677
references.citation: Mayo Clin Proc. 2002 Apr;77(4):371-83
references.pmid: 11936935
references.citation: J Clin Oncol. 2002 Jan 1;20(1):247-53
references.pmid: 11773176
references.citation: J Clin Oncol. 1989 Nov;7(11):1748-56
references.pmid: 2681557
references.citation: Cancer Res. 1993 Mar 1;53(5):1027-31
references.pmid: 7679945
references.citation: Anticancer Drugs. 1995 Dec;6 Suppl 6:7-13
references.pmid: 8718419
references.citation: J Thorac Cardiovasc Surg. 2002 Mar;123(3):466-73; discussion 473-4
references.pmid: 11882817
references.citation: Cancer. 1994 Apr 15;73(8):2087-98
references.pmid: 8156514
references.citation: Lung Cancer. 1998 Jul;21(1):1-6
references.pmid: 9792048
references.citation: Ann Thorac Surg. 1999 Dec;68(6):2053-8
references.pmid: 10616976
references.citation: Clin Lung Cancer. 2005 Dec;7 Suppl 3:S98-104
references.pmid: 16384544
references.citation: Br J Cancer. 2006 Apr 24;94(8):1099-106
references.pmid: 16622435
references.citation: J Thorac Oncol. 2008 Jan;3(1):37-45
references.pmid: 18166839
references.citation: J Thorac Cardiovasc Surg. 2000 Mar;119(3):429-39
references.pmid: 10694600
references.citation: Eur J Cancer. 1996 Feb;32A(2):243-8
references.pmid: 8664035
references.citation: Med Care. 2003 May;41(5):582-92
references.pmid: 12719681
references.citation: Eur J Cardiothorac Surg. 2006 Jul;30(1):184-9
references.pmid: 16730452
references.citation: Ann Thorac Surg. 1993 Jun;55(6):1365-73; discussion 1373-4
references.pmid: 8390230